Drug intelligence / Profile preview

Bifidobacterium pseudocatenulatum W112

Development stage: Preclinical
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Bifidobacterium pseudocatenulatum W112 is a live biotherapeutic probiotic strain originally isolated from healthy infant feces. It is being investigated for its potential therapeutic applications in mental health, hepatology, and oncology. In preclinical models, W112 has demonstrated the ability to alleviate depressive-like behaviors and liver injury induced by chronic stress by modulating the gut-liver-brain axis. Its mechanism involves the regulation of neuroendocrine activity, reduction of inflammatory markers, and restoration of gut microbiota balance. Additionally, W112 has shown promise as an adjuvant in cancer immunotherapy, specifically enhancing the efficacy of PD-1 antibody treatment in melanoma by increasing CD8+ T cell infiltration and promoting a pro-inflammatory tumor microenvironment through the enrichment of interleukin-12 (IL-12) and interferon-gamma (IFN-gamma).

Other names: B. pseudocatenulatum W112

Targets

CD8A (CD8 alpha/beta Coreceptor)IFNG (Interferon gamma)IL12 (Interleukin-12)

Beyond the preview

Go deeper on Bifidobacterium pseudocatenulatum W112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bifidobacterium pseudocatenulatum W112.

Explore the full profile